A registry study with 1,581 cases of Stenotrophomonas maltophilia blood and/or lower respiratory infections suggest Levofloxacin is a reasonable alternative to standard therapy with Trimethoprim-sulfamethoxazole.
26 Jan, 2022 | 01:40h | UTC
Commentary on Twitter
A new study in OFID suggests that mortality outcomes are similar comparing levofloxacin and TMP/SMX treatment of S. maltophilia lower respiratory tract and bloodstream infections.
?:https://t.co/80QDy3DTU9 #IDSAJournals @PaulSaxMD @DrJLi @Keith_S_Kaye @SameerKadri12 pic.twitter.com/TNxQpfT97n
— IDSA (@IDSAInfo) January 23, 2022